Autopsy report · NCT00112905
Sorafenib in Treating Patients With Regional or Metastatic Cancer of the Urothelium
Cause of deathNo reason given
Life of this trial
- Registered 4 months before it started.
- Ran for about 2 years 5 months before it stopped.
- 27 participants enrolled.
- Results were posted on the registry 3 years 1 month after it ended.
Vital statistics
- Status
- Terminated
- Phase
- Phase 2
- Sponsor
- National Cancer Institute (NCI)
- Sponsor type
- US National Institutes of Health
- Conditions
- Adenocarcinoma of the Bladder; Distal Urethral Cancer; Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter; Proximal Urethral Cancer; Recurrent Bladder Cancer; Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter
- Interventions
- sorafenib tosylate; laboratory biomarker analysis
- Participants
- 27
- Sites
- 1
- Countries
- United States
Look deeper
- The official registry record (the source of truth)
- Record history: every change the sponsor made
- Open it in the database
Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.